Key highlights
Basic Information
The subject of the sale is a 100% business share in a company operating in the segment of private medical transport services (NZDZ). The company was founded more than 30 years ago and over the course of its existence has grown into one of the leading providers of private medical transport in the region, ranking among the best in the industry in terms of the quality and age of its vehicle fleet.
The core business is the transport of patients within the framework of private medical transport services. The company provides patient transfers for health insurance companies and hospitals under contractual arrangements approved by the insurers, making the business model highly stable and protected by the regulatory framework of the healthcare sector. The customer base is diversified and long-term stable — contracts with health insurance companies are a key asset, the retention of which requires compliance with strict quality standards.
The company operates a fleet of modern ambulance vehicles with a market value of approximately CZK 23 million. It employs a total of 26 staff, of whom 18 are professional ambulance drivers; the remaining personnel cover dispatch, HR, administration and management. The operational base — vehicle parking, a service workshop and office premises totalling over 1,400 m² — is used under a lease agreement.
The company’s key strengths include its dominant regional position, a modern vehicle fleet, stable and regulated revenues from health insurance companies, and a proven management team. The current owner and managing director is willing, should the new owner wish, to remain in post and ensure a smooth handover of management. The key opportunity for an acquirer lies in the potential to consolidate the private medical transport sector in the region, expand geographic coverage, and integrate into a larger group with economies of scale.
The ideal acquirer is a consolidator in the medical transport sector, a supra-regional group active in the healthcare industry, or a strategic investor seeking a stable, regulated business with predictable cash flows.
Financial Information
| Indicator | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 28.2 mil. Kč1.2 mil. EUR | 26.7 mil. Kč1.1 mil. EUR | 30.9 mil. Kč1.3 mil. EUR | 29.3 mil. Kč1.2 mil. EUR |
| EBITDA | 5.5 mil. Kč225 ths. EUR | 6.1 mil. Kč250 ths. EUR | 7.4 mil. Kč303 ths. EUR | 7.4 mil. Kč303 ths. EUR |
| EBITDA margin | 19.5 % | 22.8 % | 23.9 % | 25.3 % |
Tangible Assets
Intangible Assets
Leases
Employees
|
Indebtedness
Total Annual Revenue
Annual Normalised EBITDA
Note: The company’s normalised EBITDA was calculated as the real profit before depreciation and interest expense that the company is capable of generating. Normalised EBITDA has been adjusted for one-off, non-recurring and non-core costs. Other Information
|
What the stated price includes
The stated price includes:
- a 100% stake in the company
- the company's receivables and liabilities at their standard level
- debt of CZK 5.1 million
The stated price does not include:
- non-operating cash in the company's bank accounts
The final structure of the transaction will be specified in the course of negotiations.
